Proteogenomics connects somatic mutations to signalling in breast cancer

Abstract

Summary Somatic mutations have been extensively characterized in breast cancer, but the effects of these genetic alterations on the proteomic landscape remain poorly understood. We describe quantitative mass spectrometry-based proteomic and phosphoproteomic analyses of 105 genomically annotated breast cancers of which 77 provided high-quality data. Integrated analyses allowed insights into the somatic cancer genome including the consequences of chromosomal loss, such as the 5q deletion characteristic of basal-like breast cancer. The 5q trans effects were interrogated against the Library of Integrated Network-based Cellular Signatures, thereby connecting CETN3 and SKP1 loss to elevated expression of EGFR, and SKP1 loss also to increased SRC. Global proteomic data confirmed a stromal-enriched group in addition to basal and luminal clusters and pathway analysis of the phosphoproteome identified a G Protein-coupled receptor cluster that was not readily identified at the mRNA level. Besides ERBB2, other amplicon-associated, highly phosphorylated kinases were identified, including CDK12, PAK1, PTK2, RIPK2 and TLK2. We demonstrate that proteogenomic analysis of breast cancer elucidates functional consequences of somatic mutations, narrows candidate nominations for driver genes within large deletions and amplified regions, and identifies therapeutic targets.

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers

“…Although emerging mass spectrometry approaches have the ability to identify adaptive responses, RPPA provides a cost-effective, efficient approach for sparse unbiased analysis of pathways involved in adaptive responses. In particular, RPPA has increased sensitivity for a number of phosphoproteins over mass spectrometry, and mass spectrometry is “blind” to a number of phosphoproteins due to a lack of convenient cleavage sites (52). …”

Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research

“…Following these advances, proteomic approaches have been used to address multiple clinical questions in the context of various cancer types. The major area of application is the profiling of cancer-relevant tissues-including the proteomes of colorectal cancer [7,8] and prostate cancer [9], as well as the subtyping of lymphoma [10] and breast cancer [11,12] patients. Although proteomics has become an extremely powerful approach for studying biomedical questions, offering unique advantages compared to other omics techniques, the functional interpretation of the vast amounts of data of a typical proteomics experiment often poses analytical challenges to the biological domain experts.…”

Identifying Abundant Immunotherapy and Other Targets in Solid Tumors

“…In MS proteins can be quantified using either a label-free approach such as spectral counting (SC), which was used by the CPTAC to profile colon cancer 8 , or by relative quantitation, which was used to profile breast and ovary tumors 9,10 . SC counts the number of times the MS instrument sampled any peptide that was assigned to a specific protein, with either full or fractional weight of ambiguous peptides were retained.…”

“…We demonstrate the potential scale of this problem by integrating CPTAC breast cancer MS data, including RNA-seq data and results from antibody-based Reversed Phase Protein Arrays (RPPA) data 9 . Analysis was restricted to the 1000 most variable breast cancer proteins identified by MS.…”